A new class of weight-loss drug just took a major step toward approval for use. In a phase 3 clinical trial, the medication retatrutide helped control blood sugar levels in participants with type 2 ...

Retatrutide weight loss drug trials recorded 28.3% average body weight loss, outpacing surgery and all existing GLP-1 ...

Retatrutide isn't supposed to be everywhere. Touted as the next generation in the GLP-1 craze, it's an experimental weight-loss drug that is not authorized outside of clinical trials. The Food and ...

Retatrutide, an experimental diabetes drug, reduced A1C levels by 2 percent and body weight by 17 percent in a new late-stage trial. Unlike rival medications, which target one or two hormone receptors ...

Please provide your email address to receive an email when new articles are posted on . Retatrutide was tied to weight loss ranging from 19% with a 4 mg dose to 28.3% with a 12 mg dose at 80 weeks. Of ...

Some people taking the investigational medication retatrutide lost an average of 30 percent of their body weight in about 2 years. The medication offers weight reduction on par with bariatric surgery.

Retatrutide is a weekly injection being studied as a treatment for obesity, type 2 diabetes, knee osteoarthritis pain, obstructive sleep apnea, chronic low back pain and liver disease. It has not been ...

Doctors warn of an "enormous" risk of overdose after testing of a popular unapproved weight loss peptide reveals the product had double the strength of what was listed on its label.

Retatrutide, a powerful experimental weight-loss drug that mimics three different hormones the body produces after eating, helped people lose 70 pounds on average, or 28% of their body weight, ...